Slide 1: CareDx - Allenex: Building a Comprehensive Global Transplant Diagnostics Leader
CareDx - Allenex Building a Comprehensive Global Transplant Diagnostics Leader Investor Conference Call April 19, 2016 ® Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding future financial position of CareDx, Inc. (“CareDx” or the “Company”),
Slide 3: Agenda
Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A
Slide 4: Compelling Strategic Rationale
Compelling Strategic Rationale Highly complementary technologies that address both pre/post transplant markets Combined annual revenue approximately $45M; Creates scale and additional growth opportunities Commercial scale and geographic diversification to support potential cross selling in EU and RO
Slide 5: Attractive Market Opportunity
Attractive Market Opportunity Post Transplant Pre Transplant Market Size: $500M Market1 $1.5B Market2 Focus: Organ Matching Rejection Monitoring Patient Eligibility Immune Suppression Dynamics: Donor Registries Novel Approach Fragmented labs Fragmented protocols Players: Thermo Fisher Immucor HistoG
Slide 6: Creating a Pre-to-Post Transplant Continuum
Creating a Pre-to-Post Transplant Continuum Longitudinal Data Reimbursement (Bundled Offering) Pre-Transplant Matching HLA Typing Kits; SSP, RT-PCR, SBT Lab Directors; HLA Labs in Tx Centers Direct Sales US/EU; distributors ROW Technology Portfolio Channel Access Synergies Post-Transplant Monitoring
Slide 7: Transplant Product Portfolio
Transplant Product Portfolio ® Description: Automated SSP platform Pre-Dispensed PCR plates Hydrolysis probe technology All-in-one hot start PCR master mix Description: 115-120 different typing kits Covers ~6,000 different HLA alleles identified to date Low and high resolution typing offerings Fast
Slide 8: Serving the Global Transplant Market
Serving the Global Transplant Market ® Total Revenues: ~$44M Sales by Geography: Sales by Product: Total Revenues: ~$44M Source: Allenex and CareDx 2015 Financial Reports
Slide 9: Agenda
Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A
Slide 10: Introduction: Allenex/Olerup Innovation in Transplantation Diagnostics
Introduction: Allenex/Olerup Innovation in Transplantation Diagnostics Olerup SSP AB pioneered the field of HLA typing in the early ’90s with the introduction of its invention: PCR-SSP (Sequence Specific Primer HLA typing) The invention by Assoc Prof Olle Olerup, founder and CEO of the company, quic
Slide 11: Olerup SSP: Pioneer of SSP Technology for Rapid HLA typing
Olerup SSP: Pioneer of SSP Technology for Rapid HLA typing ® Olerup SSP HLA Typing Kits Score 6 Interpretation Software Description: Approx. 350 different typing kits / SKU’s Covers ~14.000 different HLA alleles identified to date Both low and high resolution typing offerings Fast accurate results w
Slide 12: QTYPE: Comprehensive Automated Rapid HLA Typing
QTYPE: Comprehensive Automated Rapid HLA Typing QTYPE HLA Typing Kits Score 6 Interpretation Software Description: Automated SSP platform Pre-Dispensed PCR plates Hydrolysis probe technology All-in-one hot start PCR master mix Commercial Impact: Use on installed base of current PCR instruments (ABI
Slide 13: Strong Presence in U.S. and Europe
Strong Presence in U.S. and Europe ® Direct Sales Distributor Sales San Francisco Stockholm West Chester, PA Vienna Direct Sales Distributor Network
Slide 14: Evolution of Transplant Diagnostics
Evolution of Transplant Diagnostics ® Instrument: Sanger Sequencing Reagent: SBT Resolver™ Software: Assign™ Evolving Growth Strategy Long-Standing Partnership with CareDx Global Distribution Rights with Allenex Sequencing Next Generation Sequencing
Slide 15: Agenda
Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A
Slide 16: CareDx and Allenex at a Glance
CareDx and Allenex at a Glance (USD in MM) CareDx Allenex Combined Market Leadership Leader and innovator post- transplantation surveillance Global leading pre-transplant HLA typing diagnostics Revenue1,2 $28.1 $16.2 $44.3 Net income/loss -$13.7 $0.2 -$13.5 Employees 97 58 155 Footnotes: CareDx actu
Slide 17: Acquisition Deal Terms
Acquisition Deal Terms ® Estimated Acquisition Purchase Consideration Amounts ($ in millions) % Mix Common Stock Price Per Share Cash paid 13.6 39% Commitment to purchase units 8.0 23% Deferred payment 6.3 18% 79% Stock distributed 7.2 21% 1,375,029 5.24* 35.1 100% * Closing stock price on April 14,
Slide 18: PIPE Financing Drives Growth Initiatives
PIPE Financing Drives Growth Initiatives ® Purchase agreements to sell $14.1 million units consisting of the following securities: One share of common stock Five shares of Series A mandatorily convertible preferred stock Purchase price equivalent to $3.99 per share of common stock, assuming preferre
Slide 19: Funding Details
Funding Details ® *Pro forma assumes conversion of mandatorily convertible preferred securities **USD equivalent of debt denominated in Swedish Kroner Securities Purchase Agreement Pro Forma * Common Stock Amounts ($ in millions) Units Analysis Warrants shares Units purchased 14.2 591,860 Common sha
Slide 20: Agenda
Agenda CareDx Strategy Peter Maag Allenex Product Portfolio Anders Karlson Financial InformationCharles Constanti OutlookPeter Maag Q&A
Slide 21: Key Upcoming Milestones
Key Upcoming Milestones ® 16 Apr 2016 Close of Allenex Acquisition AlloSure Data in Heart at 2016 ISHLT AlloSure Data in Kidney QTYPE Launch May 2016 Jun 2016 H2 2016